News

Bookmark and Share

Abuse Deterrent Coalition Commends Energy & Commerce Committee Action Approving H.R. 5582

5/10/2018

Abuse Deterrent Coalition Commends Energy & Commerce Committee Action Approving H.R. 5582

Legislation Requires Federal Study of Payor Obstacles to Adoption of Modern Abuse Deterrent Technology to Fight Opioid Abuse, Misuse and Diversion

Washington, D.C. – May 9, 2018 – The Abuse Deterrent Coalition (ADC), an alliance of abuse deterrent formulation technology manufacturers, patient and issue associations and pharmaceutical manufacturers gathered to educate the public, policy makers and the FDA on the importance of Abuse Deterrent Formulations (ADFs)  technologies in the fight against prescription drug abuse, commends the House Energy & Commerce Committee for its unanimous approval of H.R. 5582, legislation to help determine why insurance payors erect barriers to the adoption of prevention technologies designed to help inhibit prescription drug abuse, misuse and diversion. The Abuse Deterrent Coalition thanks lead sponsor Congressman Buddy Carter (R-GA), and his chief co-sponsors, Representatives Dave Loebsack (D-IA), Mike Doyle (D-PA) and Tom Reed (R-NY) for the approval of this landmark legislation.  Energy & Commerce Committee Chair Greg Walden (R-OR) is also a co-sponsor of the bill

“This legislation offers the promise of an Executive Branch study to report to Congress the means and methods used by payors to either slow the uptake, or outright stymied the sale of ADFs to patients.  ADFs are part of the prevention solution to the opioid crisis. Barriers such as “fail first” or “prior authorization” limitations prevent ADFs from realizing their potential as a critical element of our federal strategy to combat opioid abuse,” said Dan Cohen, Chair of the ADC. “Representatives Carter, Loebsack, Reed and Doyle have prodded the House to take this important first step toward policy changes that mandate abuse deterrent technologies as a key element in reducing the incidents of abuse, misuse and diversion of the most abusable prescription medicines.”

The House of Representatives Energy and Commerce Committee approved H.R. 5582 by a voice vote today and it will be scheduled for a vote in the full House of Representatives in coming weeks. Prior to Committee approval, Representatives Carter, Doyle, and Loebsack all spoke in support of H.R. 5582. The legislation directs the Secretary of Health and Human Services to conduct a study on barriers to accessing abuse deterrent opioid formulations for chronic pain patients enrolled in Medicare parts C and D. Cohen noted that the Carter-Loebsack-Doyle-Reed legislation would send a critical message to policy makers that abuse deterrent technologies need to play a central role in federal policy combatting addiction moving forward.

“We believe these Representatives have advanced the cause of creating a federal policy that supports innovation to reduce the incidence of opioid abuse, misuse and diversion,” added Cohen. “Congress is now including prevention with the treatment agenda to help deal with this national problem.  They are clearly signaling the need to adopt modern technology, such as abuse deterrence, as part of our national prescription drug abuse reduction strategy.  More must be accomplished, but today’s action is the first of many steps we anticipate from the Congressional leaders such as Carter-Loebsack-Doyle-Reed who are seeking an “all of the above” approach to fight prescription opioid abuse.”

Original Release

Bookmark and Share